Roche walked away from a Phase I drug. That usually means there is something ugly in the data, either no hint of efficacy, a safety issue, or a manufacturing problem.
That does not mean that Roche is buying Dendreon. If Inovios was going to be put on the back burner, don't you think Roche would want to know that it was the successful buyer before pulling the plug on a viable drug project?
